Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights

Did the company provide any updates on its product pipeline that could affect long‑term valuation? How will the reported Q2 2025 revenue and earnings compare to analyst expectations and affect the stock price? What guidance did Lexeo Therapeutic provide for Q3 2025 and the full year, and how does it compare to consensus forecasts? Did the operational highlights include any significant clinical trial updates or regulatory milestones that could impact future cash flows? How does Lexeo's cash burn and runway look after the quarter, and will it require additional financing? What are the key drivers behind any changes in gross margin or operating expenses this quarter? How does Lexeo's performance this quarter compare to its direct competitors in the biotech/therapeutics space? Are there any new partnership, licensing, or acquisition announcements that could influence the company's strategic position? What is the market's reaction to the earnings release, and are there any notable changes in trading volume or short interest? What potential risks or uncertainties were highlighted in the MD&A that traders should monitor moving forward?